HIV-1 drug resistance genotyping from antiretroviral therapy (ART) naïve and first-line treatment failures in Djiboutian patients

Diagnostic Pathology

Amine Slim²  MohamedAliBenHadj Kacem²  Houssein Youssouf Darar¹  Asma Jlizi²  Aden Elmi Abar² 

[1] Service des Maladies Infectieuses de l’Hôpital Général Peltier, Djibouti, Republic of Djibouti;Laboratoire de Microbiologie, CHU Charles Nicolle, Tunis, Tunisie

关键词: Virological failure;    Djibouti;    Antiretroviral naive;    First-line antiretroviral therapy failure;    HIV-1 drug resistance;   

Others  :  807925
DOI  :  10.1186/1746-1596-7-138

 received in 2012-06-24, accepted in 2012-09-18,  发布年份 2012

【 摘 要 】

In this study we report the prevalence of antiretroviral drug resistant HIV-1 genotypes of virus isolated from Djiboutian patients who failed first-line antiretroviral therapy (ART) and from ART naïve patients.

【 授权许可】

   
2012 Elmi Abar et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Robert S, Michael Gottlieb S, Robert S, Howard Schanker M, Joel D, Weisman DO, Peng Thim F, Robert Wolf A, Andrew S: Pneumocystis carinii Pneumonia and Mucosal Candidiasis in Previously Healthy Homosexual Men — Evidence of a New Acquired Cellular Immunodeficiency. N Engl J Med 1981, 305:1425-1431.
• [2]Barre-Sinoussi F, et al.: Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983, 220:868-871.
• [3]Hemelaar J, Gouws E, Ghys PD, Osmanov S: Global trends in molecular epidemiology of HIV-1 during 2000–2007. AIDS 2011, 25:679-689.
• [4]Thomson MM, Perez-Alvarez L, Najera R: Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. Lancet Infect Dis 2002, 2:461-471.
• [5]Gilks CF, Crowley S, Ekpini R, et al.: The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006, 368(9534):505-510.
• [6]World Health Organization: Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. WHO, HIV Department, Geneva, Switzerland; 2006. Available at: http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf webcite. Accessed 12 December 2007
• [7]Gazzard BG, British HIV: Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008, 9:563-608.
• [8]Vergne L, Peeters M, Mpoudi-Ngole E, Bourgeois A, Liegeois F, Toure-Kane C, Mboup S, Mulanga-Kabeya C, Saman E, Jourdan J, Reynes J, Delaporte E: Genetic diversity of protease and reverse transcriptase sequences in non-subtype B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Cardiovasc Manag 2000, 38:3919-3925.
• [9]Guide d’utilisation des Antirétroviraux (ARV) chez l’adulte et l’adolescent en République de DJIBOUTI 2008. http://www.aidstar-one.com/sites/default/files/treatment/national_treatment_guidelines/Djibouti_adult_guidelines_2008.pdf webcite
• [10]Jlizi A, Ben Ammar A, El Gaaied A, Slim F, Tebourski M, Ben Mamou T, Ben C, et al.: Profile of drug resistance mutations among HIV-1-infected Tunisian subjects failing antiretroviral therapy. Arch Virol 2008, 153:1103-1108.
• [11]Abecasis AB, Vandamme AM, Lemey P: Quantifying differences in the tempo of human immunodeficiency virus type 1 subtype evolution. J Virol 2009, 83:12917-12924.
• [12]Nyombi BM, et al.: Diversity of human immunodeficiency virus type 1 subtypes in Kagera and Kilimanjaro regions Tanzania. AIDS Res Hum Retroviruses 2008, 24:761-769.
• [13]Abebe A, Lukashov VV, Pollakis G, Kliphuis A, Fontanet AL, Goudsmit J, Rinke TF, de Wit TF: Timing of the HIV-1 subtype C epidemic in Ethiopia based on early virus strains and subsequent virus diversification. AIDS 2001, 15:1555-1561.
• [14]Abebe A, Lukashov VV, Rinke De Wit TF, Fisseha B, Tegbaru B, Kliphuis A, Tesfaye G, Negassa H, Fontanet AL, Goudsmit J, Pollakis G: Timing of the introduction into Ethiopia of subcluster C′ of HIV type 1 subtype C. AIDS Res Hum Retrovir 2001, 17:657-661.
• [15]Maslin J, Rogier C, Caron M, Grandadam M, Koeck JL, Nicand E: Antiretroviral drug resistance among drug-naive HIV-1-infected individuals in Djibouti (Horn of Africa). Antivir Ther 2005, 10:855-859.
• [16]Maslin J, Rogier C, Berger F, Khamil MA, Mattera D, Grandadam M, Caron M, Nicand E: Epidemiology and genetic characterization of HIV-1 isolates in the general population of djibouti (Horn of Africa). J Acquir Immune Defic Syndr 2005, 39:129-132.
• [17]Faria NR, Suchard MA, Abecasis A, Sousa JD, Ndembi N, Bonfim I, Camacho RJ, Vandamme AM, Lemey P: Phylodynamics of the HIV-1 CRF02_AG clade in Cameroon. Infect Genet Evol 2012, 12(2):453-460.
• [18]Hemelaar J, et al.: The origin and diversity of the HIV-1 pandemic. Trends in Molecular Medicine 2011, 20:1-11.
• [19]Carr JK, Salminen MO, Albert J, Sanders-Buell E, Gotte D, Birx DL, McCutchan FE: Full genome sequences of human immunodeficiency virus type 1 subtypes G and A/G intersubtype recombinants. Virology 1998, 247:22-31.
• [20]Cornelissen M, van Den Burg R, Zorgdrager F, Goudsmit J: Spread of distinct human immunodeficiency virus type 1 AG recombinant lineages in Africa. J Gen Virol 2000, 81:515-523.
• [21]Rousseau CM, Learn GH, Bhattacharya T, Nickle DC, Heckerman D, Senica C, Christian B, Philip J, Goulder R, Bruce D, Walker Photini K, Korber BT, Mullins JI: Extensive Intra-subtype Recombination in South African HIV-1 Subtype C Infections. J Virol 2007, 81(9):4492-4500.
• [22]Darar HY, Kibangou N, Mbuzenakamwe MJ, Goulan MA, Ibrahim IM: Réponse au traitement antirétroviral chez les patients infectés par le VIH-1 suivis au Centre Yonis Toussaint de Djibouti [Abstract]. 5éme Conférence Francophone VIH/SIDA, Maroc 2010, 493(77):215. 28–31 March 2010
• [23]Kibangou N: Prise en charge des patients sous traitement ARV à Djibouti entre 2004 et 2009 [Abstract]. 5éme Conférence Francophone VIH/SIDA, Maroc 2010, 578(88):237. 28–31 March 2010
• [24]Johnson VA, Vincent C, Günthard HF, Roger P, Deenan P, Robert S, Wensing AM, Richman DD: 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 2011, 19:156-164.
• [25]Geretti AM: Clinical implications of HIV drug resistance to nucleoside and nucleotide reverse transcriptase inhibitors. AIDS Rev 2006, 8:210-220.
• [26]Theys K, Deforche K, Libin P, Camacho RJ, Van Laethem K, Vandamme AM: Resistance pathways of human immunodeficiency virus type 1 against the combination of zidovudine and lamivudine. J Gen Virol 2010, 91:1898-1908.
• [27]Van Vaerenbergh K, Van Laethem K, Albert J, Boucher CA, Clotet B, Floridia M, Gerstoft J, Hejdeman B, Nielsen C, Pannecouque C, Perrin L, Pirillo MF, Ruiz L, Schmit JC, Schneider F, Schoolmeester A, Schuurman R, Stellbrink HJ, Stuyver L, Van Lunzen J, Van Remoortel B, Van Wijngaerden E, Vella S, Witvrouw M, Yerly S, De Clercq E, Destmyer J, Vandamme AM: Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. Antimicrob Agents Chemother 2000, 44:2109-2117.
• [28]Coakley EP, Gillis JM, Hammer SM: Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS 2000, 14:F9-F15.
• [29]Shafer RW: Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev 2002, 15:247-277.
• [30]Emanuele B, Ana PC M, Victor Moreschi N, Camila DA S, Karla A, Saito AO, Mecatti MC, Santos MG, Pimentel CR, Larissa LG S, Cruz CR, de Noronha L: Histomorphometric and immunohistochemical analysis of infectious agents, T-cell subpopulations and inflammatory adhesion molecules in placentas from HIV-seropositive pregnant women. Diagn Pathol 2011, 6(101):101. 24 October 2011
• [31]Eholie SP, N’Dour CT, Cisse M, Bissagnene E, Girard PM: Observance of antiretroviral treatments African specificities. Med Mal Infect 2006, 36:443-448.
• [32]Phillips AN, Dunn D, Sabin C, et al.: UK Collaborative Group on HIV Drug Resistance, UK CHIC Study Group. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 2005, 19:487-494.
• [33]Chesney MA, Ickovics J, Hecht FM, et al.: Adherence: a necessity for successful HIV combination therapy. AIDS 1999, 13(A):S271-S278.
• [34]Bangsberg DR, Charlebois ED, Grant RM, et al.: High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 2003, 17:1925-1932.
• [35]Shah B, Walshe L, Saple DG, et al.: Adherence to antiretroviral therapy and virologic suppression among HIV-infected persons receiving care in private clinics in Mumbai, India. Clin Infect Dis 2007, 44:1235-1244.
• [36]Ahmed AA, Katlama C, Ghosn J, Guiguet M, Costagliola D: Évaluation de l’observance au traitement antirétroviral au sein d’une cohorte de 200 patients à Djibouti (2005). Eastern Mediterranean Health Journal 2007, 13(6):1286-1297.
• [37]Renoux E, Barreh Matan A, Sevre JP, et al.: Tuberculose et infection VIH: expérience du programme national de lutte antituberculeuse de Djibouti: 1990–1996. Med Trop 2002, 62:171-176.
• [38]Acina E, Morand C, Mahdi A, Morand JJ: La malnutrition en République de Djibouti: un problème majeur de santé publique. Revue de l’ISERST 1991, 5:11-15.
• [39]Little SJ, Holte S, Routy JP, et al.: Antiretroviral-drug resistance among patients recently infected with HIV. New Engl J Med 2002, 347:385-394.